M&A Deal Summary

Lineage Cell Therapeutics Acquires Asterias Biotherapeutics

On March 11, 2019, Lineage Cell Therapeutics acquired life science company Asterias Biotherapeutics

Acquisition Highlights
  • This is Lineage Cell Therapeutics’ 1st transaction in the Life Science sector.
  • This is Lineage Cell Therapeutics’ 1st transaction in the United States.
  • This is Lineage Cell Therapeutics’ 1st transaction in California.

M&A Deal Summary
Date 2019-03-11
Target Asterias Biotherapeutics
Sector Life Science
Buyer(s) Lineage Cell Therapeutics
Deal Type Add-on Acquisition
Advisor(s) Raymond James - Investment Banking (Financial)
Dentons (Legal)

Target

Asterias Biotherapeutics

Fremont, California, United States
website
Asterias Biotherapeutics, Inc. is a biotechnology company engages in the emerging field of regenerative medicine. The company’s proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of oncology and neurology.

Search 192,907 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lineage Cell Therapeutics

Carlsbad, California, United States

website

Category Company
Founded 1990
Sector Life Science
Employees57
Revenue 1M USD (2019)
DESCRIPTION

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. BioTime’s programs are based on the Company’s proprietary cell-based therapy platform which is utilized to develop and manufacture specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer. Lineage Cell Therapeutics was founded in 1990 and is based in Alameda, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Mergr

Product

Company

Legal